Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms DORA
- 04 Jun 2019 Study design was presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 08 Nov 2018 Planned End Date changed from 1 Apr 2020 to 1 Dec 2020.
- 08 Nov 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2020.